Dongcheng subsidiary gets FDA approval for prostate cancer drug trial

Yantai Dongcheng Biochemicals' subsidiary LNC PHARMA announced its 225Ac-LNC1011 injection received a Study May Proceed letter from the US FDA, allowing Phase I clinical trials to begin.

The alpha-particle radioactive therapy targets PSMA-positive advanced prostate cancer and is designed to offer enhanced cell-killing efficacy while reducing damage to healthy tissues. The company has invested approximately 1.42bn yuan in the project.

No similar products are currently on the market, making this a novel approach in prostate cancer treatment.